Merck fits the bill perfectly,and they need a fix for NSCLC. Huge market,and Merck knows it. BMY is likely to take Axal/EU/US and maybe a HOT app for Cervix on top. Amgn must want the HOT app for NSCLC,but I doubt they want to pay what it`s worth after they took the whole NEO platform for less money then what Adxs probably wants and deserves for this App. I say Merck takes it and we`re saved from the death grip of Amgn,and we`re stronger then ever before,because then the PSA/HOT will likely be grabbed by Merck as well,and then we`ll have a run on HOT apps going forward.